Wire · opportunities
Beren's Niemann-Pick drug Lembaz cleared by FDA
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 November 2026 · Fusion42 review
The FDA has approved Beren Therapeutics' Lembaz (adrabetadex) for treating Niemann-Pick disease type C in children and adults with infantile-onset, marking the first therapy shown to extend survival in this rare condition.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 17 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
Your rare disease biotech now faces a new bar for clinical proof: survival extension is proven possible in Niemann-Pick type C. Expect payers and partners to demand similarly impactful endpoints over symptomatic relief.
◆ Coverage
8 sources · first reported 17 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics